ProPhase Labs, Inc. Other Nonoperating Expense
ProPhase Labs, Inc. (PRPH) reported Other Nonoperating Expense of $41.00 thousand for the 3-month period ending 2020-09-30, per its 10-Q filed 2020-11-19.
Discontinued › Income Statement › Other Income
us-gaap:OtherNonoperatingExpense · last filed 2020-11-19
- ProPhase Labs, Inc. other nonoperating expense for the quarter ending 2020-09-30 was $41.00K.
| Period end | Other Nonoperating Expense 3 month | Other Nonoperating Expense 9 month |
|---|---|---|
| 2020-09-30 | $41.00K 10-Q · filed 2020-11-19 | $41.00K 10-Q · filed 2020-11-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |